Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4956 - Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Management of Systemic Therapy Toxicities;  Supportive Care and Symptom Management

Tumour Site

Gastrointestinal Cancers

Presenters

Carin Lunenburg

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

C.A.T.C. Lunenburg1, L.M. Henricks2, E. Dreussi3, F.P. Peters4, M. Fiocco5, D. Meulendijks6, G. Toffoli3, H. Guchelaar7, J.J. Swen7, E. Cecchin3, J.H.M. Schellens8, H. Gelderblom9

Author affiliations

  • 1 Department Of Medical Oncology, Leiden University Medical Center (LUMC), 2333ZA - Leiden/NL
  • 2 Department Of Clinical Pharmacology, Division Of Medical Oncology, The Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 3 Experimental And Clinical Pharmacology Unit, National Cancer Institute, Aviano/IT
  • 4 Department Of Radiotherapy, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 5 Medical Statistics, Department Of Biomedical Data Sciences, Leiden University Medical Centre, 2333ZA - Leiden/NL
  • 6 Dutch Medicines Evaluation Board, CBG-MEB, Utrecht/NL
  • 7 Department Of Clinical Pharmacy And Toxicology, Leiden University Medical Center, Leiden/NL
  • 8 Department Of Clinical Pharmacology, Division Of Medical Oncology, The Netherlands Cancer Institute, Amsterdam/NL
  • 9 Department Of Medical Oncology, Leiden University Medical Center (LUMC), Leiden/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4956

Background

Prospective DPYD genotyping prevents severe fluoropyrimidine-induced toxicity by decreasing initial dosages in DPYD variant allele carriers. However, fluoropyrimidine dosages in chemoradiation therapy are already lower compared to other fluoropyrimidine-containing regimens. It is unknown if recommended dose reductions of pharmacogenetic guidelines are valid for DPYD variant allele carriers receiving fluoropyrimidines in chemoradiation therapy. The aim of this study was to investigate severe toxicity in DPYD variant allele carriers receiving chemoradiation therapy.

Methods

Three databases were used, containing data on patients who received fluoropyrimidine-based chemoradiation therapy. Frequencies of severe (grade ≥3) toxicity in DPYD variant allele carriers (DPYD*2A, DPYD*13, c.2846A>T or c.1236G>A) receiving upfront fluoropyrimidine dose reductions according to current pharmacogenetic dosing guidelines (50 or 75% depending on the variant), and DPYD variant allele carriers receiving full-dose were compared to DPYD wild-type patients receiving standard dose fluoropyrimidines in chemoradiation therapy.

Results

DPYD variant allele carriers treated with standard dosages (N = 34) showed an increased risk of severe gastrointestinal (adjusted OR = 2.58, 95% CI = 1.02-6.53, P = 0.045) or severe haematological (adjusted OR = 4.19, 95% CI = 1.32-13.25, P = 0.015) toxicity compared to wild-type patients (N = 771). DPYD variant allele carriers who received dose reductions (N = 22) showed a comparable frequency of severe gastrointestinal toxicity, but a higher frequency of severe haematological toxicity, compared to wild-type patients. The mean duration of hospitalisation was significantly shorter in DPYD variant allele carriers who received dose reductions compared to DPYD variant allele carriers treated with standard dosages (4 versus 23 days, P = 0.010).

Conclusions

Standard fluoropyrimidine dosages in chemoradiation therapy resulted in an increased risk of severe toxicity in DPYD variant allele carriers. Fluoropyrimidine dose reductions for DPYD variant allele carriers should also be applied in patients receiving chemoradiation therapy.

Clinical trial identification

Legal entity responsible for the study

Leiden University Medical Centre.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

C.A.T.C. Lunenburg: Previously supported by an unrestricted grant from Roche Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.